Press Centre

February 9, 2018

VOLUNTARY NATIONWIDE RECALL: ONE LOT OF ALYSENA™ 28 (Levonorgestrel and Ethinyl Estradiol tablets, USP 100 mcg/20 mcg) DUE TO POSSIBILITY OF BROKEN/CHIPPED TABLETS

September 1, 2017

VOLUNTARY NATIONWIDE RECALL: ONE LOT OF APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray) Apotex Standard, 0.4MG/METERED DOSE DUE TO POSSIBILITY OF NON-SPRAYING PUMP

March 31, 2016

Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets

Apobiologix®, a Division of Apotex Inc., today launched Grastofil®, its first subsequent entry biologic (SEB) approved in Canada.

March 24, 2016

Apotex Launches First Generic Version of Merck's Nasonex®

Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States.

March 16, 2015

Apotex Announces Realignment And Executive Leadership Team To Better Serve The Healthcare Market in Canada And Globally

Dr. Jeremy B. Desai, President and CEO of Apotex, announced today a significant realignment in its structure and operating model. The objective of the realignment is to better serve customers through the establishment of defined lines of business by aligning internal process streams in support of company strategies. Under the new structure, Apotex will now operate along 3 core Lines of Business.

February 17, 2015

ApoPharma Announces Health Canada Approval of Ferriprox (deferiprone)

ApoPharma Inc., today announced that Health Canada has granted approval of Ferriprox (deferiprone), an oral iron chelator for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.

February 17, 2015

Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil™)

Apotex Inc., a rising competitor in the global biosimilars market, announced today that, as of February 13th, 2015, the US Food and Drug Administration has accepted for filing the company's application for Filgrastim [Grastofil™], a biosimilar version of Amgen's Neupogen®.

December 17, 2014

Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim

Apotex Inc., the largest Canadian owned pharmaceutical company, announced today that the US Food and Drug Administration has accepted for filing the company's application for pegfilgrastim, a biosimilar version of Amgen's Neulasta®.

September 26, 2014

Setting The Record Straight: Products Are Safe And Effective

Apotex Statement: There has been a great deal of confusion regarding two of our facilities in Bangalore, India. We need to set the record straight. Apotex has two manufacturing facilities located in Bangalore, India.

September 11, 2014

Medicine to Treat 1 in 10 Haitians Arrives in Port-au-Prince

Health officials anticipate that up to 50 percent of the population will be affected by the outbreak. The most recent numbers for Haiti record nearly 65,000 suspected cases. Apotex Inc. donates more than $2.2 M in medical supplies

August 26, 2014

NAFTA Tribunal Decision Supports FDA and Its Actions

Apotex Inc., the largest Canadian owned pharmaceutical company, announced today that an arbitration tribunal rejected Apotex's claims that the FDA violated NAFTA by prohibiting imports of Apotex products from two plants in Ontario, Canada.

October 5, 2012

New Apotex Offices in Saudi Arabia Will Help Expand Trade in Quality, Affordable Pharmaceuticals

Apotex Inc. the largest Canadian owned pharmaceutical company, announced today the opening of new offices in Saudi Arabia to meet the growing demand for affordable quality pharmaceuticals manufactured in Canada.

October 1, 2012

10 Products Divested to AA Pharma

As part of ongoing efforts of reviewing our product portfolio within the evolving generic market landscape, we have made the decision to divest 10 older products within the Canadian market to AA Pharma Inc. Many of these products have been in the market since the 60s and 70s and have been subject to decreasing demand and increasing costs which has placed continued pressure on their commercial viability.

April 2, 2012

Apotex delivers second largest generic blockbuster in Canadian history

Apotex Inc. the largest Canadian owned pharmaceutical company, launched today Apo-Rosuvastatin, a generic version of Crestor® produced by AstraZeneca. The Apotex product is 100% Canadian made by employees and facilities dedicated to ensuring that Canada remains a global strength in generic product introduction. With annual Crestor® brand sales in Canada of over $700 million, generic Rosuvastatin represents the second largest generic product launch in this market to date.

Search by: